Partners
Business Development Opportunities
Collaboration and licensing of our platform technology are key elements of Affinity’s development strategy. We actively pursue diverse forms of international strategic collaboration and innovation with leading global biopharmaceutical companies and academic institutions, to rapidly advance next-generation therapies targeting the tumor microenvironment, and address the significant unmet medical needs of cancer patients worldwide.

Affinity’s platform technology is protected by strong patents in all major global markets, and we have already entered into multiple research and development agreements with global biopharmaceutical companies, including technology platform licensing deals.

We look forward to welcoming more partners to establish strategic partnerships with us and explore various collaboration models.

  • Out-Licensing Partnerships
  • Co-Development
  • Joint Venture Projects
Out-Licensing Partnerships
Affinity’s technology platforms encompass TMEA‑ALDC, TMEA‑SMDC, TMEA‑ADC, TMEAboby, TMEAakine and TMEA‑TCE, enabling the engineering of diverse molecules including small‑molecule therapeutics, cytokines, antibodies and fusion proteins. The platforms feature robust scalability and broad application potential. Affinity independently develops multiple candidate molecules at different stages of research and development, with potential First‑in‑class or Best‑in‑class profiles. The Company actively pursues global collaboration and out‑licensing opportunities.
Co-Development
Affinity actively seeks collaborative R&D and strategic partnerships with global biopharmaceutical companies and academic institutions, leveraging Affinity’s innovative platform to achieve complementary resource advantages and diversify the pipeline. We can modify partners’ molecules, including small-molecule drugs, cytokines, antibodies, and fusion proteins, to design next-generation drug candidates that are selectively activated in the tumor microenvironment.
Joint Venture Projects
For specific fields and projects, Affinity may establish joint venture partnerships to co-develop and commercialize innovative drug candidates in the global market. This collaboration accelerates the delivery of transformative therapies that bring significant value to patients and society.
Partners

R&D and Business Development Cooperation:

Email: bd@affinity.net.cn